id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S9359 R32738 |
Tomson (Valproate), 2018 | Neural tube defects | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 29.46 [3.90;222.36] C | 16/1,381 1/2,514 | 17 | 1,381 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9333 R32558 |
Campbell (Valproate) (Controls exposed to Lamotrigine, sick), 2014 | Neural tube defect | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 11.29 [2.54;50.12] | 13/1,220 2/2,098 | 15 | 1,220 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10295 R37702 |
Vajda (Valproate) (Controls exposed to Lamotrigine, sick), 2013 | Neural Tube Malformations | at least 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
17.90 [1.02;314.95] C excluded (control group) |
7/271 0/315 | 7 | 271 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10296 R37706 |
Vajda (Valproate) (Controls unexposed, sick), 2013 | Neural Tube Malformations | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 8.34 [0.47;147.07] C | 7/271 0/147 | 7 | 271 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10231 R37482 |
Hernández-Díaz (Valproate) (Controls exposed to Lamotrigine, sick), 2012 | Neural tube defects | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No Controls: mixed indications | 9.78 [1.78;53.63] C | 4/323 2/1,562 | 6 | 323 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9331 R32550 |
Bànhidy (Valproate), 2011 | Neural tube defects | throughout pregnancy | case control | unexposed, sick | Adjustment: No Matched | 2.00 [0.10;39.08] C | 1/6 1/11 | 2 | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9312 R35336 |
Mawer (Valproate) (Controls exposed to Lamotrigine, sick), 2010 | Neural Tube Malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.70 [0.01;35.84] C excluded (control group) |
0/53 0/37 | 0 | 53 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9317 R35340 |
Mawer (Valproate) (Controls unexposed, disease free), 2010 | Neural Tube Malformations | 1st trimester | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
1.80 [0.07;44.79] C excluded (control group) |
0/53 1/285 | 1 | 53 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9318 R35344 |
Mawer (Valproate) (Controls unexposed, sick), 2010 | Neural Tube Malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.77 [0.01;39.72] C | 0/53 0/41 | 0 | 53 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9335 R32576 |
Canger (Valproate), 1999 | Neural tube defects | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 7.00 [0.37;132.29] C | 5/44 0/25 | 5 | 44 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 7 studies | 9.34 [4.08;21.40] | 52 | 3,298 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Valproate; 2: Valproate) (Controls exposed to Lamotrigine, sick; 3: Valproate) (Controls unexposed, sick; 4: Valproate) (Controls exposed to Lamotrigine, sick; 5: Valproate; 6: Valproate) (Controls unexposed, sick; 7: Valproate;
Asymetry test p-value = 0.0927 (by Egger's regression)
slope=3.9702 (0.8805); intercept=-1.6322 (0.7867); t=2.0748; p=0.0927
excluded 9312, 9317, 10295